Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

Nano-Synergy Engineering fibroblast-targeted mRNA therapies as clinically-focused adjuvants for unlocking tissue regeneration in arthritis

Coordinator
The Chancellor, Masters and Scholars of the University of Oxford, United Kingdom
Runs
1 September 2025 to 31 August 2027
Status
Running
EU funding
€260k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101209884

What the project is doing

In the project's own words, from its summary on CORDIS.

As a Marie Skłodowska-Curie (MSC) fellow, I aim to engineer clinically focused mRNA formulations for rewriting the biology of synovial cells and unlocking regeneration in rheumatoid arthritis, and expand the capabilities of current Disease Modifying Anti-Rheumatic Drugs (DMARDs). The current first-line therapies for rheumatoid arthritis (RA), DMARDs, effectively manage inflammation but do not regenerate destroyed bone tissue, leading to lifelong disability and pain.

We hypothesize that reprogramming specific synovial cell types by combining targeted mRNA delivery with approved DMARD therapies can restore the pathological tissue state in arthritis back to a healthy state and enable long-term joint repair. This project, Nano-Synergy, will be supervised by global leader in materials chemistry and tissue engineering Prof. Dame Molly Stevens at the Kavli Institute for Nanoscience Discovery (University of Oxford).

I will collaborate with tissue biologists Prof. Chris Buckley and Prof. Mark Coles at the Kennedy Institute of Rheumatology (University of Oxford), the world’s premiere rheumatology research centre. In the host Stevens group, I will rationally engineer mRNA nanodelivery systems which specifically deliver payloads to joint synovial cells by using bio-orthogonal chemistry and revolutionary techniques for characterizing nanoparticle physicochemical properties.

I will demonstrate that mRNA synergizes with DMARDs to reprogram arthritis at the cellular level by adapting a state-of-the-art organoid system utilized by Buckley and Coles which spatially and transcriptionally recapitulates human arthritis, and then demonstrate tissue regeneration using an animal model. In summary, as a biomedical engineer and immunologist trained in RNA delivery and animal models of tissue injury, I will integrate unrivalled expertise and capabilities in engineering and rheumatology at Oxford to pioneer new regenerative therapies.

Topics

Who is involved

OrganisationCityCountryRole
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI